Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases
Status: | Recruiting |
---|---|
Conditions: | Breast Cancer, Cancer, Cancer, Cancer |
Therapuetic Areas: | Oncology |
Healthy: | No |
Age Range: | 18 - Any |
Updated: | 4/6/2019 |
Start Date: | July 7, 2016 |
Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases
This randomized phase II trial studies how well cisplatin works with or without veliparib in
treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast
cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known if cisplatin is more effective with or without veliparib in
treating patients with triple-negative and/or BRCA mutation-associated breast cancer.
treating patients with triple-negative breast cancer and/or BRCA mutation-associated breast
cancer that has come back or has or has not spread to the brain. Drugs used in chemotherapy,
such as cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. It is not yet known if cisplatin is more effective with or without veliparib in
treating patients with triple-negative and/or BRCA mutation-associated breast cancer.
PRIMARY OBJECTIVES:
I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on
progression-free survival (PFS) in each of the following groups: patients with germline BRCA
(gBRCA) mutation-associated breast cancer, patients with germline BRCA wild-type breast
cancer who have evidence of BRCAness phenotype, and patients with germline BRCA wild-type
breast cancer who do not have evidence of BRCAness phenotype.
II. To compare the efficacy of cisplatin with or without ABT-888 on PFS in patients with
triple negative and/or gBRCA mutation-associated breast cancer and brain metastases. (Brain
Metastases Cohort)
SECONDARY OBJECTIVES:
I. For patients with gBRCA mutation associated breast cancer or triple-negative breast cancer
(TNBC) with or without BRCAness phenotype, to compare the efficacy of cisplatin with or
without ABT-888 on overall survival (OS), response rate, and clinical benefit rate.
II. To compare the differential benefit of ABT-888 across the three groups using both PFS and
OS as outcomes.
III. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with
or without ABT-888 on OS.
IV. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with or
without ABT-888 on intracranial and extracranial response rates (intracranial by Response
Assessment Neuro-Oncology Criteria [RANO] and extracranial by Response Evaluation Criteria in
Solid Tumors version 1.1 [RECIST 1.1]).
V. To compare toxicities of ABT-888 to placebo in each of the four groups separately.
TRANSLATIONAL OBJECTIVES:
I. To evaluate the impact of homologous recombination deficiency score (independent of other
BRCAness markers) on response rate (RR) and PFS in patients treated with chemotherapy versus
chemotherapy plus ABT-888.
II. To evaluate the overlap among various markers utilized to define the BRCAness phenotype.
III. To evaluate the combined impact of PAM50 basal subtype and BRCAness phenotype on RR and
PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.
IV. To evaluate the impact of BRCA1 mRNA expression (independent other BRCAness markers) on
response rate (RR) and PFS in patients treated with chemotherapy versus chemotherapy plus
ABT-888.
V. Application of somatic BRCAness phenotype markers on metastatic tumor tissue to identify
patients likely to benefit from platinum-based therapy and ABT-888.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive cisplatin intravenously (IV) over 1 hour on day 1 and placebo orally
(PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 9 weeks for 54 weeks,
every 18 weeks until progression, and then every 6 months for up to 5 years after
progression.
I. To compare the efficacy of cisplatin with or without ABT-888 (veliparib) on
progression-free survival (PFS) in each of the following groups: patients with germline BRCA
(gBRCA) mutation-associated breast cancer, patients with germline BRCA wild-type breast
cancer who have evidence of BRCAness phenotype, and patients with germline BRCA wild-type
breast cancer who do not have evidence of BRCAness phenotype.
II. To compare the efficacy of cisplatin with or without ABT-888 on PFS in patients with
triple negative and/or gBRCA mutation-associated breast cancer and brain metastases. (Brain
Metastases Cohort)
SECONDARY OBJECTIVES:
I. For patients with gBRCA mutation associated breast cancer or triple-negative breast cancer
(TNBC) with or without BRCAness phenotype, to compare the efficacy of cisplatin with or
without ABT-888 on overall survival (OS), response rate, and clinical benefit rate.
II. To compare the differential benefit of ABT-888 across the three groups using both PFS and
OS as outcomes.
III. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with
or without ABT-888 on OS.
IV. For patients in the brain metastases cohort, to compare the efficacy of cisplatin with or
without ABT-888 on intracranial and extracranial response rates (intracranial by Response
Assessment Neuro-Oncology Criteria [RANO] and extracranial by Response Evaluation Criteria in
Solid Tumors version 1.1 [RECIST 1.1]).
V. To compare toxicities of ABT-888 to placebo in each of the four groups separately.
TRANSLATIONAL OBJECTIVES:
I. To evaluate the impact of homologous recombination deficiency score (independent of other
BRCAness markers) on response rate (RR) and PFS in patients treated with chemotherapy versus
chemotherapy plus ABT-888.
II. To evaluate the overlap among various markers utilized to define the BRCAness phenotype.
III. To evaluate the combined impact of PAM50 basal subtype and BRCAness phenotype on RR and
PFS in patients treated with chemotherapy versus chemotherapy plus ABT-888.
IV. To evaluate the impact of BRCA1 mRNA expression (independent other BRCAness markers) on
response rate (RR) and PFS in patients treated with chemotherapy versus chemotherapy plus
ABT-888.
V. Application of somatic BRCAness phenotype markers on metastatic tumor tissue to identify
patients likely to benefit from platinum-based therapy and ABT-888.
OUTLINE: Patients are randomized to 1 of 2 treatment arms.
ARM I: Patients receive cisplatin intravenously (IV) over 1 hour on day 1 and placebo orally
(PO) twice daily (BID) on days 1-14. Courses repeat every 21 days in the absence of disease
progression or unacceptable toxicity.
ARM II: Patients receive cisplatin IV over 1 hour on day 1 and veliparib PO BID on days 1-14.
Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed up every 9 weeks for 54 weeks,
every 18 weeks until progression, and then every 6 months for up to 5 years after
progression.
Inclusion Criteria:
- Patients must have metastatic and/or recurrent (distant or locoregionally recurrent)
breast cancer and be HER2 non-over expressing per 2013 American Society of Clinical
Oncology (ASCO)-College of American Pathologists (CAP) HER testing guidelines (0 or 1+
by immunohistochemistry [IHC]; and/or HER2 ratio < 2.0 and HER2 copy number < 4
signals/cell by in-situ hybridization [ISH])
- Local Regional Recurrence
- In the breast (after preserving therapy)
- In the chest wall (after mastectomy)
- In the ipsilateral/parasternal/infra-or supraclavicular lymph nodes
- In the skin of the chest wall (not breast)
- In the reconstructed breast
- Patients must also meet at least one of the following criteria:
- Triple negative: histologically confirmed primary and/or metastatic site that is
estrogen receptor (ER)-negative (=< 1%), progesterone receptor (PR)-negative (=<
1%), and HER2-negative
- BRCA mutation: previously confirmed deleterious breast cancer 1, early onset
(BRCA1) or breast cancer 2, early onset (BRCA2) germline mutation or suspected
deleterious BRCA1 or BRCA2 germline mutation if the classification being used is
the 5-tier classification; documentation of germline test results are required
- Patients must have measurable or non-measurable disease; patients must have a
chest/abdominal/pelvis computed tomography (CT) scan (or positron emission tomography
[PET]/CT of diagnostic quality, conventional or spiral) prior to registration; if the
patient is unable to undergo CT with IV contrast due to allergy or renal
insufficiency, a non-contrast CT may be performed; all scans needed for assessment of
measurable disease must be performed within 28 days prior to registration;
non-measurable disease must be assessed within 42 days prior to registration; all
disease must be assessed and documented on the Baseline Tumor Assessment Form
- Patients must have adequate tissue available and must agree to have specimens
submitted for germline BRCA deoxyribonucleic acid (DNA) sequencing and other
correlative studies
- NOTE: Blood for BRCA mutation testing is to be collected and submitted after
registration but before treatment
- Patients must have had =< 1 prior cytotoxic regimen for metastatic disease (unless
enrolling in the Progressive Brain Metastases Cohort); note that endocrine and
immunotherapies do not count as cytotoxic regimens
- Patients must have completed any prior radiation therapy and hormonal therapy at least
14 days prior to registration
- Patients must not have received prior cisplatin or poly (adenosine diphosphate
[ADP]-ribose) polymerase (PARP) inhibitors; prior carboplatin in the
adjuvant/neoadjuvant setting and prior treatment with iniparib is allowed, if
completed more than 12 months prior to study entry
- Patients must not have received any chemotherapy within 14 days prior to registration
- Patients must not have received any immunotherapy, biologic or any investigational
drug within 28 days prior to registration; patients must not have received bevacizumab
within 42 days prior to registration
- Patients may receive bisphosphonates or denosumab concurrently with study treatment;
if started prior to registration, it must be started at least 7 days prior to
registration
- Patients must have recovered to =< grade 2 following a significant adverse event or
toxicity attributed to previous anti-cancer treatment except neurotoxicity which must
be =< grade 1
- Patients must have a performance status of 0-2 by Zubrod criteria
- Absolute neutrophil count (ANC) of >= 1,500/mL (within 21 days prior to registration);
patients must not have had a blood transfusion within 28 days prior to registration
- Hemoglobin >= 10 g/dL (within 21 days prior to registration); patients must not have
had a blood transfusion within 28 days prior to registration
- Platelet count >= 100,000/ mL (within 21 days prior to registration); patients must
not have had a blood transfusion within 28 days prior to registration
- Bilirubin =< 1.5 mg/dL (or =< 3.0 mg/dL if due to Gilbert's syndrome or if liver
metastases are present) (within 21 days prior to registration)
- Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x
institutional upper limit of normal (IULN) (or =< 5 x IULN if liver metastases are
present) (within 21 days prior to registration)
- Patients must have adequate renal function with serum creatinine level =< IULN within
21 days prior to registration
- Patients must have serum chemistries (including potassium and magnesium) within 21
days prior to registration to obtain baseline values
- Patients must not have a clinically relevant hearing impairment >= grade 2
- Patients must be able to swallow whole capsules
- Patients with a history of uncontrolled seizure disorder; including focal or
generalized seizure may not have had a seizure within one year prior to registration
- Patients with known brain metastases must either meet the additional criteria and
enroll as part of the Progressive Brain Metastases Cohort, or have clinically
controlled neurologic symptoms, defined as surgical excision and/or radiation therapy
followed by 14 days of stable neurologic function prior to registration; patients with
previously incidentally discovered or asymptomatic brain metastasis(es) must receive
surgical excision and/or radiation therapy prior to registration; patients with
progressive brain metastases following prior treatment are not eligible for the
Standard Cohort, but may be considered for the Progressive Brain Metastases Cohort
- Patients must not have treatment-related acute myeloid leukemia (AML)
(t-AML)/myelodysplastic syndrome (MDS) or features suggestive of AML/MDS
- Patients must not have had prior allogeneic bone marrow transplant or double umbilical
cord blood transplantation
- Patients must not have any incidence of or uncontrolled medical illness (e.g. active
cardiac symptoms, active systemic infection, etc.) that would limit the patient's
ability to participate in the protocol
- Patients must not have baseline peripheral neuropathy that exceeds grade 1
- Patients must have a complete history and physical examination within 28 days prior to
registration
- Patients of childbearing potential must not be pregnant (negative pregnancy test) or
nursing; men and women of reproductive potential must have agreed to use an effective
contraceptive method for 6 months after completion of study treatment; a woman is
considered to be of "reproductive potential" if she has had menses at any time in the
preceding 12 consecutive months; in addition to routine contraceptive methods,
"effective contraception" also includes heterosexual celibacy and surgery intended to
prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a
hysterectomy, bilateral oophorectomy or bilateral tubal ligation; however, if at any
point a previously celibate patient chooses to become heterosexually active during the
time period for use of contraceptive measures outlined in the protocol, he/she is
responsible for beginning contraceptive measures
- No other prior malignancy is allowed except for the following: adequately treated
basal cell or squamous cell skin cancer, in situ cervical cancer, adequately treated
stage I or II cancer from which the patient is currently in complete remission, or any
other cancer from which the patient has been disease free for five years
- Patients must be informed of the investigational nature of this study and must sign
and give written informed consent in accordance with institutional and federal
guidelines
- As part of the Oncology Patient Enrollment Network (OPEN) registration process the
treating institution's identity is provided in order to ensure that the current
(within 365 days) date of institutional review board approval for this study had been
entered in the system
- Progressive Brain Metastases Cohort
- S1416 is one study with two cohorts; patients who have progressive brain
metastases after surgical excision and/or intracranial radiation will be in the
Progressive Brain Metastases Cohort and will require a baseline magnetic
resonance imaging (MRI); patients with previously treated brain metastases,
stable disease and stable neurologic function for 14 days prior to trial
registration will be in the Standard Cohort and may obtain MRI of the brain at
the physician's discretion; randomization and treatment is the same for both
cohorts
- In addition to all of the previous eligibility criteria, patients with
progressive brain metastases who do not satisfy the conditions to enroll in the
standard cohort (neurologic stability for 14 days following surgery and/or
radiation therapy) must also meet the following criteria to enroll as part of the
brain metastases cohort:
- Patients with progressive brain metastases must have a baseline brain MRI
within 28 days prior to registration; brain metastases must be progressive
and >= 10 mm in longest dimension on radiographic imaging AFTER prior
intracranial radiation (IR) therapy (i.e., whole brain radiation therapy
[WBRT], stereotactic radiosurgery [SRS], gamma knife [GK] or local
equivalent); patients must not have evidence of diffuse leptomeningeal
disease on brain MRI or by previously documented cerebrospinal fluid (CSF)
cytology; discrete dural metastases are permitted; there must be no evidence
of hemorrhage or impending herniation on baseline brain imaging; patients
with contraindication to gadolinium-enhanced MRI imaging are not eligible
- Patients must be on a stable or decreasing dose of steroids for >= 7 days
prior to registration
- If patient had an open brain biopsy, at least 28 days must have elapsed
between biopsy and registration
- Patients enrolling in the Progressive Brain Metastases Cohort can have
received up to 3 prior lines of cytotoxic chemotherapy for metastatic
disease; note that for enrollment in the standard cohort, patients must have
had =< 1 prior cytotoxic regimen for metastatic disease
We found this trial at
800
sites
Cincinnati, Ohio 45219
Principal Investigator: John C. Morris
Phone: 513-558-4553
Click here to add this to my saved trials
1201 Camino de Salud Northeast
Albuquerque, New Mexico 87131
Albuquerque, New Mexico 87131
(505) 272-4946
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-925-0366
University of New Mexico Cancer Center It’s been 40 years since the New Mexico State...
Click here to add this to my saved trials
361 Old Belgrade Road
Augusta, Maine 04330
Augusta, Maine 04330
(207) 621-6100
Principal Investigator: Thomas H. Openshaw
Phone: 207-626-4855
Harold Alfond Center for Cancer Care MaineGeneral's Harold Alfond Center for Cancer Care (HACCC) is...
Click here to add this to my saved trials
2545 Schoenersville Rd
Bethlehem, Pennsylvania 18017
Bethlehem, Pennsylvania 18017
(484) 884-2200
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Lehigh Valley Hospital - Muhlenberg At Lehigh Valley Health Network, we continually go the extra...
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
666 Elm Street
Buffalo, New York 14263
Buffalo, New York 14263
(716) 845-2300
Principal Investigator: Ellis G. Levine
Phone: 800-767-9355
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
1 Hurley Plaza
Flint, Michigan 48503
Flint, Michigan 48503
(810) 262-9000
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Hurley Medical Center From its founding in 1908, Hurley Medical Center has devoted itself to...
Click here to add this to my saved trials
3551 Roger Brooke Dr
Fort Sam Houston, Texas 78234
Fort Sam Houston, Texas 78234
(210) 916-4141
Principal Investigator: John S. Renshaw
Phone: 210-916-4837
Brooke Army Medical Center Brooke Army Medical Center (BAMC) is the Flagship of Army Medicine!...
Click here to add this to my saved trials
301 University Blvd
Galveston, Texas 77555
Galveston, Texas 77555
(409) 772-1011
Principal Investigator: Avi B. Markowitz
Phone: 409-772-1950
University of Texas Medical Branch Established in 1891 as the University of Texas Medical Department,...
Click here to add this to my saved trials
100 Michigan Street Northeast
Grand Rapids, Michigan 49503
Grand Rapids, Michigan 49503
616.391.9000
Principal Investigator: Kathleen J. Yost
Helen DeVos Children's Hospital at Spectrum Health Helen DeVos Children's Hospital, located in Grand Rapids,...
Click here to add this to my saved trials
2500 N State St
Jackson, Mississippi 39216
Jackson, Mississippi 39216
(601) 984-1000
Principal Investigator: Barbara S. Craft
Phone: 601-815-6700
University of Mississippi Medical Center The University of Mississippi Medical Center, located in Jackson, is...
Click here to add this to my saved trials
524 South Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 341-7654
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Methodist Hospital Our healthcare system serves patients and families throughout southwest Michigan and northern...
Click here to add this to my saved trials
200 North Park Street
Kalamazoo, Michigan 49007
Kalamazoo, Michigan 49007
(269) 382-2500
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
West Michigan Cancer Center In 1994, Borgess Health Alliance and Bronson Healthcare Group opened the...
Click here to add this to my saved trials
4805 Northeast Glisan Street
Portland, Oregon 97213
Portland, Oregon 97213
(503) 215-1111
Principal Investigator: Gary E. Goodman
Phone: 503-215-2614
Providence Portland Medical Center We strive to give those we serve exceptional, compassionate health care...
Click here to add this to my saved trials
Seattle, Washington 98104
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
Click here to add this to my saved trials
1100 Fairview Avenue North
Seattle, Washington 98109
Seattle, Washington 98109
(206) 667-5000
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Fred Hutchinson Cancer Research Center At Fred Hutchinson Cancer Research Center, our interdisciplinary teams of...
Click here to add this to my saved trials
825 Eastlake Ave E
Seattle, Washington 98109
Seattle, Washington 98109
(206) 288-7222
Principal Investigator: Julie R. Gralow
Phone: 800-804-8824
Seattle Cancer Care Alliance Seattle Cancer Care Alliance (SCCA) is a cancer treatment center that...
Click here to add this to my saved trials
Aberdeen, Washington 98520
Principal Investigator: Gary E. Goodman
Phone: 360-412-8958
Click here to add this to my saved trials
1200 Old York Road
Abington, Pennsylvania 19001
Abington, Pennsylvania 19001
(215) 481–2000
Principal Investigator: Willard G. Andrews
Phone: 215-481-2402
Abington Memorial Hospital Abington Memorial Hospital (AMH) is a 665-bed, regional referral center and teaching...
Click here to add this to my saved trials
Adrian, Michigan 49221
Principal Investigator: Rex B. Mowat
Phone: 517-265-0116
Click here to add this to my saved trials
200-298 Avenida Doctor Pedro Albizu Campos
Aguadilla, 00603
Aguadilla, 00603
Principal Investigator: Luis Baez-Diaz
Phone: 787-997-2222
Click here to add this to my saved trials
Akron, Ohio 44304
Principal Investigator: Bradley T. Clifford
Phone: 330-375-6101
Click here to add this to my saved trials
1 Akron General Avenue
Akron, Ohio 44307
Akron, Ohio 44307
Principal Investigator: Esther H. Rehmus
Phone: 866-223-8100
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Albuquerque, New Mexico 87109
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Albuquerque, New Mexico 87110
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-559-6113
Click here to add this to my saved trials
Albuquerque, New Mexico 87102
Principal Investigator: Ursa A. Brown-Glaberman
Phone: 505-272-0530
Click here to add this to my saved trials
Alexandria, Louisiana 71301
Principal Investigator: John T. Cole
Phone: 318-448-6976
Click here to add this to my saved trials
Allentown, Pennsylvania 18103
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
Amarillo, Texas 79106
Principal Investigator: Brian T. Pruitt
Phone: 806-212-1985
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Ames, Iowa 50010
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
Anaconda, Montana 59711
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Click here to add this to my saved trials
Anacortes, Washington 98221
Principal Investigator: Gary E. Goodman
Phone: 206-215-3086
Click here to add this to my saved trials
Anaheim, California 92806
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Anchorage, Alaska 98508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99504
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
Anchorage, Alaska 99508
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Click here to add this to my saved trials
2000 E Greenville St
Anderson, South Carolina 29621
Anderson, South Carolina 29621
(864) 512-4640
Principal Investigator: John E. Doster
Phone: 864-512-4651
AnMedical Health Cancer Center Cancer is the general term for a group of more than...
Click here to add this to my saved trials
5301 McAuley Drive
Ann Arbor, Michigan 48197
Ann Arbor, Michigan 48197
734-712-3456
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Saint Joseph Mercy Hospital St. Joseph Mercy Ann Arbor Hospital is a 537-bed teaching hospital...
Click here to add this to my saved trials
1500 East Medical Center Drive
Ann Arbor, Michigan 48109
Ann Arbor, Michigan 48109
800-865-1125
Principal Investigator: Anne F. Schott
University of Michigan Comprehensive Cancer Center The U-M Comprehensive Cancer Center's mission is the conquest...
Click here to add this to my saved trials
Asheville, North Carolina 28803
Principal Investigator: Raymond Thertulien
Phone: 828-650-8037
Click here to add this to my saved trials
1625 Maple Lane
Ashland, Wisconsin 54806
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Ashland, Wisconsin 54806
Principal Investigator: Bret E. Friday
Phone: 218-786-3308
Click here to add this to my saved trials
Auburn, California 95602
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Auburn, California 95603
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Augusta, Georgia 30912
Principal Investigator: Sharad A. Ghamande
Phone: 706-721-2388
Click here to add this to my saved trials
Aurora, Colorado 80012
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
1501 S Potomac St
Aurora, Colorado 80012
Aurora, Colorado 80012
(303) 695-2600
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Medical Center of Aurora At The Medical Center of Aurora and Centennial Medical Plaza patients...
Click here to add this to my saved trials
12605 East 16th Avenue
Aurora, Colorado 80045
Aurora, Colorado 80045
720-848-0000
Principal Investigator: Jose I. Mayordomo
Phone: 720-848-0650
University of Colorado Hospital, Site Top medical professionals, superior medicine and progressive change make University...
Click here to add this to my saved trials
2000 Ogden Ave
Aurora, Illinois 60504
Aurora, Illinois 60504
(630) 978-6200
Principal Investigator: Maria T. Grosse-Perdekamp
Phone: 630-978-6212
Rush - Copley Medical Center Rush-Copley is proud to be the leading provider of health...
Click here to add this to my saved trials
1500 Red River Street
Austin, Texas 78701
Austin, Texas 78701
Principal Investigator: Om N. Pandey
Phone: 512-324-7991
Click here to add this to my saved trials
3325 Pocahontas Road
Baker City, Oregon 97814
Baker City, Oregon 97814
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
Bakersfield, California 93301
Principal Investigator: Eve T. Rodler
Phone: 661-323-4673
Click here to add this to my saved trials
Baldwin Park, California 91706
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Ballwin, Missouri 63011
Principal Investigator: Jay W. Carlson
Phone: 314-251-7058
Click here to add this to my saved trials
6701 N Charles St
Baltimore, Maryland 21204
Baltimore, Maryland 21204
(443) 849-2000
Principal Investigator: Madhu Chaudhry
Phone: 443-849-3706
Greater Baltimore Medical Center The 255-bed medical center (acute and sub-acute care) is located on...
Click here to add this to my saved trials
489 State St
Bangor, Maine 04401
Bangor, Maine 04401
(207) 973-7000
Principal Investigator: Thomas H. Openshaw
Phone: 207-973-4274
Eastern Maine Medical Center Located in Bangor, Eastern Maine Medical Center (EMMC) serves communities throughout...
Click here to add this to my saved trials
4305 New Shepherdsville Road
Bardstown, Kentucky 40004
Bardstown, Kentucky 40004
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Baton Rouge, Louisiana 70809
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70816
Principal Investigator: John T. Cole
Phone: 225-761-5346
Click here to add this to my saved trials
Baton Rouge, Louisiana 70836
Principal Investigator: John T. Cole
Phone: 504-703-8712
Click here to add this to my saved trials
265 Fremont St
Battle Creek, Michigan 49017
Battle Creek, Michigan 49017
(269) 245-8166
Principal Investigator: Kathleen J. Yost
Phone: 616-391-1230
Bronson Battle Creek As a proud member of the Battle Creek community, we believe everyone...
Click here to add this to my saved trials
Beaver, Pennsylvania 15009
Principal Investigator: Rachel C. Jankowitz
Phone: 724-773-7616
Click here to add this to my saved trials
3535 Pentagon Boulevard
Beavercreek, Ohio 45431
Beavercreek, Ohio 45431
Principal Investigator: Howard M. Gross
Phone: 937-775-1350
Click here to add this to my saved trials
2500 Bellevue Medical Center Drive
Bellevue, Nebraska 68123
Bellevue, Nebraska 68123
Principal Investigator: Jairam Krishnamurthy
Phone: 402-559-6941
Click here to add this to my saved trials
Bellflower, California 90706
Principal Investigator: Jonathan A. Polikoff
Phone: 800-398-3996
Click here to add this to my saved trials
Bellingham, Washington 98225
Principal Investigator: Gary E. Goodman
Phone: 360-715-4133
Click here to add this to my saved trials
800 Farson Street
Belpre, Ohio 45714
Belpre, Ohio 45714
(740) 401-0417
Principal Investigator: Timothy D. Moore
Phone: 800-523-3977
Strecker Cancer Center-Belpre The Memorial Health System's Strecker Cancer Center, Belpre combines the clinical expertise...
Click here to add this to my saved trials
Bemidji, Minnesota 56601
Principal Investigator: Preston D. Steen
Phone: 218-333-5000
Click here to add this to my saved trials
Bend, Oregon 97701
Principal Investigator: Gary E. Goodman
Phone: 541-706-2909
Click here to add this to my saved trials
Berkeley, California 94704
Principal Investigator: Ari D. Baron
Phone: 415-209-2686
Click here to add this to my saved trials
Billings, Montana 59101
Principal Investigator: Benjamin T. Marchello
Phone: 800-996-2663
Click here to add this to my saved trials
1233 North 30th Street
Billings, Montana 59101
Billings, Montana 59101
406-237-7000
Principal Investigator: Keren Sturtz
Phone: 406-969-6060
Saint Vincent Healthcare The Sisters of Charity of Leavenworth, Kansas, founded St. Vincent Healthcare in...
Click here to add this to my saved trials
Billings, Montana 59102
Principal Investigator: Keren Sturtz
Phone: 800-648-6274
Click here to add this to my saved trials
300 N. Seventh St.
Bismarck, North Dakota 58501
Bismarck, North Dakota 58501
(701) 323-6000
Principal Investigator: Preston D. Steen
Phone: 701-323-5760
Sanford Bismarck Medical Center Whether your stay in our hospital is one day for same...
Click here to add this to my saved trials
Bloomington, Illinois 61701
Principal Investigator: James L. Wade
Phone: 217-876-4740
Click here to add this to my saved trials
1505 Eastland Drive
Bloomington, Illinois 61701
Bloomington, Illinois 61701
309-662-2102
Principal Investigator: Bryan A. Faller
Phone: 309-243-3605
Illinois CancerCare-Bloomington Illinois CancerCare, P.C. is a comprehensive practice treating patients withcancer andblood diseases. Our...
Click here to add this to my saved trials
Boardman, Ohio 44512
Principal Investigator: Howard M. Gross
Phone: 330-629-7500
Click here to add this to my saved trials
Boise, Idaho 83706
Principal Investigator: Benjamin T. Marchello
Phone: 734-712-3671
Click here to add this to my saved trials
100 E Idaho St
Boise, Idaho 83712
Boise, Idaho 83712
(208) 381-2711
Principal Investigator: Gary E. Goodman
Phone: 907-212-6871
Saint Luke's Mountain States Tumor Institute For more than 100 years, St. Luke
Click here to add this to my saved trials
Bolivar, Missouri 65613
Principal Investigator: Rakesh Gaur
Phone: 800-328-6010
Click here to add this to my saved trials
Bonne Terre, Missouri 63628
Principal Investigator: Bryan A. Faller
Phone: 314-996-5569
Click here to add this to my saved trials
Boone, Iowa 50036
Principal Investigator: Debra M. Prow
Phone: 515-956-4132
Click here to add this to my saved trials
1100 Balsam Ave
Boulder, Colorado 80304
Boulder, Colorado 80304
(303) 440-2273
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Boulder Community Hospital Founded in 1922 as a community-owned and operated not-for-profit hospital, Boulder Community...
Click here to add this to my saved trials
Boulder, Colorado 80303
Principal Investigator: Keren Sturtz
Phone: 303-777-2663
Click here to add this to my saved trials
915 Highland Blvd
Bozeman, Montana 59715
Bozeman, Montana 59715
(406) 414-5000
Principal Investigator: Benjamin T. Marchello
Phone: 406-969-6060
Bozeman Deaconess Hospital Bozeman Deaconess Hospital is a Joint Commission certified, licensed Level III trauma...
Click here to add this to my saved trials
Brainerd, Minnesota 56401
Principal Investigator: Bret E. Friday
Phone: 888-203-7267
Click here to add this to my saved trials
Branson, Missouri 65616
Principal Investigator: Jay W. Carlson
Phone: 417-269-4520
Click here to add this to my saved trials
Bremerton, Washington 98310
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials
Brewer, Maine 04412
Principal Investigator: Thomas H. Openshaw
Phone: 800-987-3005
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
7575 Grand River Avenue
Brighton, Michigan 48114
Brighton, Michigan 48114
Principal Investigator: Christopher M. Reynolds
Phone: 734-712-3671
Click here to add this to my saved trials
30 Lawrence Road
Broomall, Pennsylvania 19008
Broomall, Pennsylvania 19008
Principal Investigator: Nabila Chowdhury
Phone: 610-284-8237
Click here to add this to my saved trials
Brownstown, Michigan 48183
Principal Investigator: Ding Wang
Phone: 313-916-3721
Click here to add this to my saved trials
Bryan, Texas 77802
Principal Investigator: Richard L. Deming
Phone: 308-398-6518
Click here to add this to my saved trials